Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development...

LifeArc announces £5 million drug repurposing programme for motor neuron disease MEDIA RELEASE LifeArc announces £5 million drug repurposing programme for motor neuron disease LifeArc is launching new £5m programme to help find new treatments for motor neuron disease (MND).The...